Treatment of linear IgA bullous dermatosis of childhood with flucloxacillin

Linear IgA Bullous Dermatosis Associated with Ulcerative Colitis in a 14-Year-Old Boy: A Case Report

“…It has been suggested that the immunologic disturbance in patients of UC reflects an alteration in the process of antigenic presentation, resulting in an abnormal production of IgA-1 cutaneous biopsy and direct immunofluorescence assay. Corticosteroids were started i.v., (methylprednisolone 500 mg per day for 8 days), then orally (prednisone 50 mg/day) with only partial benefit [5].…”

Dermatosis IgA lineal de la infancia: reporte de un caso

“…1 Dentro de los tratamientos de segunda línea que se han reportado como útiles, encontramos la colchicina, talidomida, antibióticos (como flucloxacilina), ciclosporina, micofenolato y azatioprina. 4,12,13 La enfermedad es benigna y tiende a cursar en brotes hasta su resolución espontánea, con una duración promedio de 3 a 4 años. 1,9 Las lesiones se curan sin cicatriz, siempre que no hubieran sido excoriadas o sufrido sobreinfección.…”

Chronic Bullous Disease or Linear IgA Dermatosis of Childhood -Revisited

“…Salmonella enteritis, nonspecific gastrointestinal infections, upper respiratory tract infections and Epstein-Barr virus infection have been associated with the development of CBDC lesions [24][25][26].…”

“…Colchicine at a dose of 0.5 mg twice daily may be introduced in cases with G6PD deficiency or when there is failure or side effects of the first line therapeutic regimen [36]. Flucloxacillin, erythromycin, cotrimoxazole and miocamycin have also been administered in young patients with CBDC as monotherapy or in combination with dapsone or topical steroids, achieving a good response due to their antinflammatory properties [24,[37][38][39]. In dapsone resistant cases of CBDC, tacrolimus has showed benefit as an adjunctive topical medication [40].…”

“…In dapsone resistant cases of CBDC, tacrolimus has showed benefit as an adjunctive topical medication [40]. As a closing remark, initiation of treatment early on in the course of the disease (within 1 month) may be the decisive factor in inducing early remission [24]. The key features of CBDC are summarized in Table 2.…”